Liver X receptors bridge hepatic lipid metabolism and inflammation

Journal of Digestive Diseases

Volumn 13, Issue 2, 2012, Pages 69-74

  Liu, Yuan ^a   Qiu, de Kai ^a   Ma, Xiong ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Cholesterol metabolism; Inflammatory response; Liver X receptor; Macrophage; Nonalcoholic fatty liver disease

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ADENOSINE TRIPHOSPHATE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; LIPID; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; FATTY LIVER; HEART LEFT VENTRICLE OVERLOAD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOGENESIS; LIPOTOXICITY; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; TH1 CELL; UPREGULATION;

CHOLESTEROL; FATTY LIVER; HEPATITIS; HUMANS; LIPID METABOLISM; MACROPHAGES; ORPHAN NUCLEAR RECEPTORS;

EID: 84862960331     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00554.x     Document Type: Review

References (60)

1. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995; 9: 1033-45.
2. Peet DJ, Turley SD, Ma W etal. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998; 93: 693-704.
3. Janowski BA, Grogan MJ, Jones SA etal. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A 1999; 96: 266-71.
4. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000; 16: 459-81.
5. Lee JH, Zhou J, Xie W. PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. Mol Pharm 2008; 5: 60-6.
6. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-70.
7. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995; 377: 454-7.
8. Wagner BL, Valledor AF, Shao G etal. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 2003; 23: 5780-9.
9. Chao EY, Caravella JA, Watson MA etal. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem 2008; 51: 5758-65.
10. Ghisletti S, Huang W, Jepsen K etal. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev 2009; 23: 681-93.
11. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-31.
12. Lehmann JM, Kliewer SA, Moore LB etal. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997; 272: 3137-40.
13. Mitro N, Vargas L, Romeo R, Koder A, Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 2007; 581: 1721-6.
14. Houck KA, Borchert KM, Hepler CD etal. T0901317 is a dual LXR/FXR agonist. Mol Genet Metab 2004; 83: 184-7.
15. Lund EG, Peterson LB, Adams AD etal. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol 2006; 71: 453-63.
16. Molteni V, Li X, Nabakka J etal. N-acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J Med Chem 2007; 50: 4255-9.
17. Mitro N, Mak PA, Vargas L etal. The nuclear receptor LXR is a glucose sensor. Nature 2007; 445: 219-23.
18. Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 2001; 262: 257-65.
19. Alberti S, Schuster G, Parini P etal. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 2001; 107: 565-73.
20. Yu L, Hammer RE, Li-Hawkins J etal. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A 2002; 99: 16237-42.
21. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-14.
22. Lo Sasso G, Murzilli S, Salvatore L etal. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab 2010; 12: 187-93.
23. Naik SU, Wang X, Da Silva JS etal. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006; 113: 90-7.
24. Bradley MN, Hong C, Chen M etal. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 2007; 117: 2337-46.
25. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 2008; 7: 365-75.
26. Honzumi S, Shima A, Hiroshima A, Koieyama T, Ubukata N, Terasaka N. LXRalpha regulates human CETP expression in vitro and in transgenic mice. Atherosclerosis 2010; 212: 139-45.
27. Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 2005; 97: 177-83.
28. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004; 86: 839-48.
29. Repa JJ, Liang G, Ou J etal. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-30.
30. Schuster GU, Parini P, Wang L etal. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 2002; 106: 1147-53.
31. Higuchi N, Kato M, Shundo Y etal. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 2008; 38: 1122-9.
32. Yokoyama A, Makishima M, Choi M etal. Induction of SREBP-1c mRNA by differentiation and LXR ligand in human keratinocytes. J Invest Dermatol 2009; 129: 1395-401.
33. Ogawa S, Lozach J, Benner C etal. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122: 707-21.
34. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-19.
35. Myhre AE, Agren J, Dahle MK etal. Liver X receptor is a key regulator of cytokine release in human monocytes. Shock 2008; 29: 468-4.
36. Wang YY, Dahle MK, Agren J etal. Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock 2006; 25: 141-6.
37. Walcher D, Kümmel A, Kehrle B etal. LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb Vasc Biol 2006; 26: 1022-8.
38. Hindinger C, Hinton DR, Kirwin SJ etal. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J Neurosci Res 2006; 84: 1225-34.
39. Fowler AJ, Sheu MY, Schmuth M etal. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 2003; 120: 246-55.
40. Wu S, Yin R, Ernest R etal. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 2009; 84: 119-26.
41. Morales JR, Ballesteros I, Deniz JM etal. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008; 118: 1450-9.
42. Crisafulli C, Mazzon E, Paterniti I, Galuppo M, Bramanti P, Cuzzocrea S. Effects of liver X receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir Res 2010; 11: 19.
43. Asquith DL, Miller AM, Hueber AJ etal. Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum 2009; 60: 2655-65.
44. Fontaine C, Rigamonti E, Nohara A etal. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007; 101: 40-9.
45. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008; 18: 461-7.
46. Wang YY, Dahle MK, Steffensen KR etal. Liver X receptor agonist GW3965 dose-dependently regulates LPS-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages. Shock 2009; 32: 548-53.
47. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
48. Brunt EM. Pathology of fatty liver disease. Mod Pathol 2007; 20 (Suppl 1): S40-8.
49. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-71.
50. Wouters K, van Gorp PJ, Bieghs V etal. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48: 474-86.
51. Wouters K, van Bilsen M, van Gorp PJ etal. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 2010; 584: 1001-5.
52. Liu Y, Han X, Bian Z etal. Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease. Dig Dis Sci 2011. [Epub ahead of print].
53. Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME etal. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond) 2011; 120: 239-50.
54. Grefhorst A, Elzinga BM, Voshol PJ etal. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002; 277: 34182-90.
55. Nakamuta M, Kohjima M, Morizono S etal. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2005; 16: 631-5.
56. Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 2007; 61: 736-59.
57. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007; 282: 743-51.
58. Yamaguchi K, Yang L, McCall S etal. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74.
59. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008; 19: 295-300.
60. McClain CJ, Barve S, Deaciuc I. Good fat/bad fat. Hepatology 2007; 45: 1343-6.